Edgar H. Castellanos MD a Medical Corporation

Edgar H. Castellanos MD a Medical Corporation was paid $2.15M by Medicaid between Jan 2018 and Nov 2024, across 16 billing codes. Its largest line is G0481, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed — 60% of everything it billed.

Compared with peers

Next to other Family Medicine Physician providers in California

Rank by total paid#107 of 2,511

Median peer was paid$13K

This provider vs. median168×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	5,879	$339K
2019	7,571	$396K
2020	7,615	$371K
2021	8,002	$324K
2022	7,011	$265K
2023	5,505	$220K
2024incomplete	3,859	$238K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	60%	10,854	9,987	$1.30M
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	26%	17,002	15,576	$551K
99215	Doctor's office visit, returning patient (complex)Prolong outpt/office vis	11%	3,539	3,247	$236K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	1.5%	1,717	1,631	$33K
81025		<1%	2,524	2,369	$8K
20553		<1%	138	126	$6K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	74	65	$5K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	1,343	1,228	$4K
99205	Prolong outpt/office vis	<1%	37	37	$3K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	<1%	307	293	$3K
80305		<1%	4,580	4,312	$3K
81000		<1%	3,226	3,069	$3K

4 more codes

99204	Doctor's office visit, new patient (more involved)	<1%	14	$2K
90686		<1%	44	$713.50
82948		<1%	30	$83.20
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	13	$38.91

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCASTELLANOS, EDGAR (PRESIDENT)